Bayesian Effective Biological Dose Determination in Immunotherapy Response Trial

Souvik Banerjee, Triparna Bose, Vijay M. Patil, Atanu Bhattacharjee () and Kumar Prabhash
Additional contact information
Souvik Banerjee: Indian Institute of Technology-Dhanbad
Triparna Bose: Symbiosis Statistical Institute
Vijay M. Patil: Tata Memorial Hospital, Tata Memorial Centre
Atanu Bhattacharjee: Tata Memorial Centre
Kumar Prabhash: Tata Memorial Hospital, Tata Memorial Centre

Annals of Data Science, 2023, vol. 10, issue 1, No 10, 209-223

Abstract: Abstract Immunotherapy, especially checkpoint inhibitors, have transformed the treatment of cancer. Unlike chemotherapy, checkpoint inhibitors modify and enable the patient's immune system to fight cancer, thus prolonging survival. The conventional maximum tolerable dose finding designs were used for dose-finding in checkpoint inhibitors studies. These proved to be unsuitable as in the majority of checkpoint inhibitors there was no appearance of toxicity. Hence doses were selected using pharmacokinetic and pharmacodynamic modelling. However, these doses produce plasma levels of the drug, which are far higher than the levels required for its optimal action. Further increment in dose in phase 1 settings was not associated with an increment in response or survival. Considering the cost implications and scarcity of these resources probably a dose much higher than necessary is administered. The need of the hour is to define a dose beyond which in the majority of patients, there won't be an incremental benefit in cancer-related outcomes. The current challenge is that to best of our knowledge, and no statistical model exists to find the minimally effective dose of the checkpoint inhibitors. Therefore, here we propose a Bayesian design to determine the effective biological dose (EBD) for immunotherapy trials. This work is about the preparation of methodology with two scenarios, (1) EBD of checkpoint inhibitors administered as monotherapy (2) EBD of checkpoint inhibitors administered as a combined therapy.

Keywords: Immunotherapy; Effective biological dose; Maximum tolerable dose; Toxicity; Inhibitors; Modelling (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40745-021-00335-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aodasc:v:10:y:2023:i:1:d:10.1007_s40745-021-00335-y

Ordering information: This journal article can be ordered from
https://www.springer ... gement/journal/40745

DOI: 10.1007/s40745-021-00335-y

Access Statistics for this article

Annals of Data Science is currently edited by Yong Shi

More articles in Annals of Data Science from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().